Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1235-1242

  Grandis, Jennifer R ^a   Lai, Stephen Y ^b   Koppikar, Priya ^b   Thomas, Sufi M ^b   Childs, Erin E ^b   Egloff, Ann Marie ^b   Seethala, Raja R ^b   Branstetter, Barton F ^b   Gooding, William E ^b   Muthukrishnan, Ashok ^b   Mountz, James M ^b   Lui, Vivian W Y ^b   Shin, Dong M ^b   Agarwala, Sanjiv S ^b   Johnson, Rita ^b   Couture, Larry A ^b   Myers, Eugene N ^b   Johnson, Jonas T ^b   Mills, Gordon ^b   Argiris, Athanassios ^b  

^a University of Pittsburgh School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTISENSE DNA; PNGVL1 U6 EGFRAS DNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANTISENSE GENE; ANTISENSE THERAPY; ANTISENSE VECTOR; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; EGFRAS GENE; FEMALE; GENE SEQUENCE; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME;

AGED; CARCINOMA, SQUAMOUS CELL; DNA, ANTISENSE; FEMALE; FLUORODEOXYGLUCOSE F18; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 62449303549     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.8251     Document Type: Article

References (31)

1. Bernard W, Stewart P: Cancer Facts and Figures, in World Health Organization: World Cancer Report. London, United Kingdom, IACR Press, 2003
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
3. List MA, Siston A, Haraf D, et al: Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination. J Clin Oncol 17:1020-1028, 1999
4. Trotti A, Bellm LA, Epstein JB, et al: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 66:253-262, 2003
5. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459, 2005
6. Rubin Grandis J, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
7. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
8. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
9. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004
10. Vermorken JB, Trigo J, Hitt R, et al: Open- label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007
11. Karamouzis MV, Grandis JR, Argiris A: Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70-82, 2007
12. Baselga J, Trigo JM, Bourhis J, et al: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568-5577, 2005
13. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Co-operative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005
14. Agulnik M, da Cunha Santos G, Hedley D, et al: Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25:2184-2190, 2007
15. Rubin Grandis J, Chakraborty A, Melhem MF, et al: Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 15:409-416, 1997
16. He Y, Zeng Q, Drenning SD, et al: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90:1080-1087, 1998
17. Zeng Q, Kanter PM, Dhir R, et al: Lack of toxicity of EGFR antisense gene therapy. J Exp Ther Oncol 2:174-186, 2002
18. Thomas SM, Zeng Q, Dyer KF, et al: Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther 10:518-528, 2003
19. Greene F, Page D, Fleming I, et al: AJCC Cancer Staging Manual, (ed 6). New York, NY, Springer-Verlag, 2002
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
22. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
23. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
24. GrandisJR, Drenning SD, Chakraborty A, et al: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102:1385-1392, 1998
25. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98:295-303, 1999
26. Cross D, Burmester JK: Gene therapy for cancer treatment: Past, present and future. Clin Med Res 4:218-227, 2006
27. Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129, 2006
28. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53 deficient human tumor cells. Science 274:373-376, 1996
29. Avril NE, Weber WA: Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43:189-204, 2005
30. Nabel GJ, Nabel EG, Yang ZY, et al: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307-11311, 1993
31. Hui KM, Ang PT, Huang L, et al: Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 4:783-790, 1997